Fundraising Fox
🦊/Companies
Sign in

i2O Therapeutics

Saratoga, US · Founded 2019 · Delaware corporation · 6 employees on LinkedIn · 4 known investors

Find your way into i2O Therapeutics

254 people in our graph share verified history with the i2O Therapeutics team — schools, employers, funds. One of them is your warm intro.

Wesley Chanunlockedknows Ravi Srinivasan · together at Massachusetts Institute of Technology (overlapped)
×10knows the team · via Massachusetts Institute of Technology
knows the team · via i2O Therapeutics

Biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections using ionic liquid technology

Biotech

Founders & leadership

i2O Therapeutics was founded in 2019 by Mitragotri Mitragotri and Ravi Srinivasan.

MM
Mitragotri MitragotriCo-founder
RSRavi Srinivasan
Ravi SrinivasaninCo-founder, President and CEO2021–2023Ravi Srinivasan is a biotech executive and scientist who has led multiple companies from founding through exit, raised over $100 million in capital, and overseen product development across clinical trial phases. He holds inventor credits on more than 30 patent families, including the Microjet Patch-pump technology.

Investors · 4

7G BioVenturesBurlingame
Sanofi VenturesCambridge · $5M
JDRF T1D Fundreported · 2 sourcesBoston

Also in the syndicate · 1

Colorcon Ventures

Reported raises · per SEC filings

Form D private placements

$43.9M disclosed across 6 rounds · 2019–2023

▶$3.5MraisedOct 2023 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher GagliardiDirector
  • Kurt GravesExecutive Officer, Director
  • Anthony AiudiDirector
Offering amount
$4M
Amount sold
$3.5M
First sale
Sep 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$33.5MraisedOct 2022 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ravi SrinivasanExecutive Officer, Director
  • Christopher GagliardiDirector
  • Kurt GravesDirector
  • Samir MitragotriExecutive Officer, Director
  • Anthony AiudiDirector
Offering amount
$42M
Amount sold
$33.5M
First sale
Jul 2022
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.3MraisedJan 2022 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Samir MitragotriExecutive Officer, Director
  • Kurt GravesDirector
  • Ravi SrinivasanExecutive Officer, Director
  • Katie ElliasDirector
  • Christopher GagliardiDirector
Offering amount
$3M
Amount sold
$2.3M
First sale
Oct 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$600KraisedDec 2020 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Samir MitragotriExecutive Officer, Director
  • Christopher GagliardiDirector
  • Ravi SrinivasanExecutive Officer, Director
  • Katie ElliasDirector
Offering amount
$600K
Amount sold
$600K
First sale
Nov 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedMar 2020 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Samir MitragotriExecutive Officer, Director
  • Katie ElliasDirector
  • Christopher GagliardiDirector
  • Ravi SrinivasanExecutive Officer, Director
Offering amount
$3.2M
Amount sold
$3.2M
First sale
Mar 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$800KraisedJul 2019 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mitragotri MitragotriExecutive Officer, Director
  • Ravi SrinivasanExecutive Officer, Director
Offering amount
$4M
Amount sold
$800K
First sale
Jun 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

i2O Therapeutics Receives Strategic Investment from Colorcon Ventures and Enters into Research Collaboration with Colorcon - BioSpacebiospace.com · Dec 2020i2O Therapeutics Raises $4 million in Seed Funding Co-led by Sanofi Ventures and JDRF T1D Fund - BioSpacebiospace.com · Apr 2020Wyss Institute spinoff i2O Therapeutics raises $4M in seed funding - Boston Business Journalbizjournals.com · Apr 2020

Frequently asked questions

What does i2O Therapeutics do?
Biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections using ionic liquid technology
Who founded i2O Therapeutics?
i2O Therapeutics was founded by Mitragotri Mitragotri, Ravi Srinivasan in 2019.
Who are i2O Therapeutics's investors?
i2O Therapeutics's investors include 7G BioVentures, Sanofi Ventures, JDRF T1D Fund.
How much funding has i2O Therapeutics raised?
i2O Therapeutics has disclosed $43.9M raised across 6 rounds.
Where is i2O Therapeutics headquartered?
i2O Therapeutics is headquartered in Saratoga, US.